Hematological oncology · 2010
Genomic profiling of Richter's syndrome: recurrent lesions and differences with de novo diffuse large B-cell lymphomas.
Сравнительное исследованиеСтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Scandurra Marta, Rossi Davide, Deambrogi Clara, Rancoita Paola M V, Chigrinova Ekaterina, Mian Michael, Cerri Michaela, Rasi Silvia, Sozzi Elisa, Forconi Francesco, Ponzoni Maurilio, Moreno Santiago M, Piris Miguel A, Inghirami Giorgio, Zucca Emanuele, Gattei Valter, Rinaldi Andrea, Kwee Ivo, Gaidano Gianluca, Bertoni Francesco
Аннотация
Richter's syndrome (RS) represents the transformation of chronic lymphocytic leukaemia (CLL) to aggressive lymphoma and is mostly represented by diffuse large B-cell lymphoma (DLBCL), with a post-germinal centre (GC) phenotype, clonally related to the pre-existing CLL. RS has a very poor prognosis and its pathogenetic mechanisms are poorly understood. In order to gain additional hints in RS pathogenesis, we performed a genome-wide DNA profiling study of 13 RS phases and eight matched CLL phases using the Affymetrix Human Mapping 250K NspI SNP arrays. Individual genomic profiles were heterogeneous, with no individual lesions occurring in more than half of the cases. However, several observations suggest that MYC pathway might be involved in RS. The 13q13.3-qter region containing MIRHG1 (MIR-17-92), a cluster of microRNA interacting with c-MYC, was acquired at the time of transformation. The 13q gain was coupled with the gain of c-MYC and loss of TP53. Translocation of c-MYC was acquired at transformation in a fraction of cases and this event appeared mutually exclusive with gain of MIRHG1. MYCN, a c-MYC homologue, was also recurrently gained. By comparing RS with 48 de novo DLBCL, RS presented a significantly lower prevalence of deletions affecting the PRDM1 and TNFAIP3, genes on 6q, known to be associated with a post-GC phenotype. In conclusion, the genomic profile of RS seems to differ from what observed in de novo DLBCL and in other transformed DLBCL. Genomic lesions occurring in RS are heterogeneous suggesting the existence of different RS subsets, possibly due to different transforming mechanisms. A deregulation of MYC pathway might represent one of the main transformation events in the pathogenesis of a subset of RS clonally related to the previous CLL.
Предметные рубрики MeSH
Chromosome AberrationsChromosomes, Human, Pair 6DNA-Binding ProteinsDisease ProgressionGene Expression ProfilingGene Rearrangement, B-LymphocyteGenes, mycGenes, p53HumansIntracellular Signaling Peptides and ProteinsLeukemia, Lymphocytic, Chronic, B-CellLymphoma, Large B-Cell, DiffuseMicroRNAsNuclear ProteinsPhenotypePositive Regulatory Domain I-Binding Factor 1RecurrenceRepressor ProteinsSequence DeletionSyndromeTumor Necrosis Factor alpha-Induced Protein 3